HEC53856
/ HEC Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 15, 2025
HEC53856-RAD-102: HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Completed | N=60 ➔ 40
Enrollment change • Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
May 15, 2025
HEC53856-RAD-103: Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
June 14, 2021
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Sunshine Lake Pharma Co., Ltd.
New P1 trial • Anemia • Hematological Disorders • CRP • VEGFA
June 14, 2021
Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Sunshine Lake Pharma Co., Ltd.
New P1 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease • CRP • VEGFA
1 to 4
Of
4
Go to page
1